Starling Oncology (STLN) Stock
What Starling Oncology's price implies, from its SEC filings.
Key numbers
- Revenue growth
- +34.6%
- Operating margin
- -3.4%
What Starling Oncology's price implies
Starling Oncology's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Starling Oncology's 10-K filings.
Starling Oncology revenue and free cash flow
FY2020–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $203M | $252M | $324M | $393M | $503M |
| Net income | -$11M | $152,000 | -$83M | -$65M | -$61M |
| Free cash flow | -$36M | -$67M | -$41M | -$30M | -$28M |
| EPS (diluted) | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 |
| Operating margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
Where the revenue comes from
By segments, fiscal 2025. By year
Superinvestors who own STLN
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held STLN in their latest 13F.
Starling Oncology insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of STLN in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from STLN's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Starling Oncology compares
Starling Oncology's P/FCF is higher than 55% of Healthcare companies and 70% of the 2,359 companies with a P/FCF figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| P/FCF | 55% | 70% |
| Revenue growth | 77% | 86% |
| Operating margin | 49% | 23% |
Questions about Starling Oncology
Are Starling Oncology insiders buying the stock?
No open-market insider purchases of STLN in the last 12 months, according to SEC Form 4 filings.
Companies like Starling Oncology
Charming Medical Ltd (MCTA)$504MStrata Critical Medical, Inc. (SRTA)$540MAuna S.A. (AUNA)$334MCommunity Health Systems Inc (CYH)$306MNutex Health Inc. (NUTX)$1.3BInnovAge Holding Corp (INNV)$1.3BPennant Group Inc (PNTG)$1.3BCompass Pathways Plc (CMPS)$1.3BAMN Healthcare Services Inc (AMN)$1.5B All Healthcare stocks→Prices and ratios as of Nov 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.